anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The MIMO Study Group proposes to conduct a prospective randomized controlled trial in order to determine whether a low implant density cohort has equivalent clinical and radiographic results to a high implant density cohort. This study is proposed as a trial of equivalence. The null hypothesis is that significant differences exist in percent major Cobb angle correction between high- and low-implant density cohorts for Lenke 1A curve types, the most common scoliotic curve pattern (73). Consecutive qualifying patients will be screened and enrolled by high-volume spine surgeons at 14 sites and randomized to spinal instrumentation with a low- or high-density screw pattern. Patients will return at 3-months, 1-year, and 2-years for exam, radiographs, and collection of patient-reported outcome scores. The Harms Study Group Foundation will serve as a collaborating organization and will provide database development and management, secure online data collection, centralized radiographic measurements, and data quality control. The University of Minnesota team will lead study design, protocol development, IRB/data use agreement contracts, patient randomization, and statistical analysis, including quarterly data review. Imaging will be obtained either with an EOS system or using a calibration belt during the radiographs, which allows for subsequent with the 3D modeling of the deformity. Six enrolling sites currently have this capability (EOS - Montreal, St. Louis, Iowa, Mayo, DuPont, and San Diego). An additional five sites already have calibration belts - Dallas, New York, Baltimore, Boston, U. of Rochester), and new calibration belts will be fabricated for the additional sites. The Montreal site will supervise collection of radiographic data with 3D capability and assist with troubleshooting and radiographic quality control. Although the study is primarily powered to detect change in percent correction of the major coronal curve, preliminary data will be gathered on axial and sagittal plane correction as well as complications, surgical factors, and patient-reported outcomes.
The invention discloses a blood-nourishing and marrow-boosting prescription for treating infant hydrocephalus. The prescription is composed of the following components in parts by weight: 6 to 10 parts of oriental waterplantain rhizome, 3 to 6 parts of osbeckia chinensis, 2 to 6 parts of bidentate achyranthes, 5 to 8 parts of arborvitae seed, 3 to 6 parts of bunge cherry seed, 4 to 6 parts of rhizoma arisaematis, 6 to 12 parts of saposhnicovia divaricata, 3 to 6 parts of dahurian angelica root, 4 to 8 parts of valeriana wallichii, 6 to 9 parts of fried bighead atractylodes rhizome, 6 to 10 parts of raspberry, 2 to 4 parts of white stiff silkworm, 4 to 8 parts of Chinese yam, 4 to 7 parts of poria cocos, 3 to 5 parts of kendir, and 5 to 10 parts of cornus officinalis. The prescription is developed on the traditional Chinese medicine theory. The physical and chemical properties of each component and the pharmacologic actions of each component are all taken into account. A preparation method that can obtain stable and reasonable active components is developed. The prescription has the functions of percolating dampness, inducing diuresis, tonifying the spleen, harmonizing the stomach, nourishing blood, regulating qi, and boosting essence and marrow. The raw materials are all traditional Chinese herbals, and do not have any side or toxic effect. The raw materials are easily-available and cheap, and the economic burden for patients can be reduced.
Impedance cardiography helps determine whether vasoconstriction or an elevated cardiac output is occurring. The test is easy to perform and non invasive. The treatment for an elevated cardiac output in pregnancy is a beta-blocker while a vasodilator is used for vasoconstriction. If a beta-blocker is given to someone that vasoconstricted, this might make the cardiovascular parameters worse, leading to no improvement in future pregnancy issues. Likewise, if a vasoconstricting drug is given to someone with an elevated cardiac output, it could potentially make the cardiovascular parameters worse.

All centers in the United States that choose to prescribe an antihypertensive medication for use in pregnancy do so by trial and error, whereas impedance cardiography can help the clinician choose the best medication from the start. Many pregnant patient patients have chronic hypertension and this population is at increased risk for superimposed preeclampsia and other pregnancy complications. The current recommendation for pregnancy is to NOT treat mild hypertension because studies have not shown any benefit. These studies, have also not shown any harm. Prior studies that have shown no benefit to treatment of mild hypertension in pregnancy may be hampered by choosing the wrong antihypertensive medication, thereby not improving the rate of superimposed preeclampsia and other pregnancy related complications.
Systems and methods of predicting documents associated with meetings between participants are provided. For example, participant data may be obtained that indicates one or more previously accessed notes associated with the first participant. The participant data may be input into a machine-learned note prediction model that includes a neural network. The neural network may generate one or more context vectors describing the participant data. Data indicative of a predicted access note may be received as output of a machine-learned note prediction model based at least in part on the context vector. The predicted access note may include a set of predicted information expected to be included in a subsequently generated access note associated with the first participant.
A composition for tissue degradation and removal and disinfection is provided for dental and medical applications. It can function as a single intra-canal irrigant that eradicates microorganisms as it facilitates the debridement of a root canal system. It contains one or more hydoxides, a thioglycolate compound, sodium hypochlorite, sodium chloride, sodium chlorate, oxygen, and water, such as lime water and purified water, The thioglycolate compound is capable of degrading a cell by disrupting disulfide bonds in its proteins. The sodium hypochlorite enhances its function. The composition may also incorporate mineral oil, urea, cetearyl alcohol, D&C yellow No. 8, chromium hydroxide, theobroma cocoa seed butter, iron oxides, fragrances, lanolin, and/or ceteareth-20. It is effective against Enterococcus faecalis.
The present invention is directed to novel anti-cancer compounds and methods of treating and/or inhibiting cancer in patients, including metastatic cancer, recurrent cancer and drug resistant cancers, including multiple drug resistant cancers. Compounds according to the present invention provide anti-cancer activity, at least in part, by virtue of their nucleotide intercalating activity through the use of analogs of (−)lomaiviticin A, a potent anticancer agent which exhibits cytotoxicity through its principal mechanism of cleavage and to a lesser extent, its intercalation of cellular polynucleotides, especially DNA. In additional embodiments, compounds according to the present invention are also conjugated and/or linked to other bioactive agents, especially agents which selectively target cancer cells (cancer cell targeting moiety or CCTM) to target and increase the delivery of the anticancer agent to the cancer cell. These targeting agents include folate receptor-targeted moieties, other cancer binding moieties such as PMSA binding moieties as otherwise described herein and antibodies, including single chain variable fragment antibodies (scFv antibodies). Pharmaceutical compositions based upon these novel compounds are also disclosed pursuant to the present invention. Methods of treating, inhibiting and/or reducing the likelihood of cancer, including metastatic and recurrent cancer and drug resistant, including multiple drug resistant cancer in a patient are also disclosed.
PURPOSE:To provide the subject composition containing a cationic surfactant, an ester oil and a polysiloxane in a specified ratio, capable of prevention of drying of the skin easy to dry, free from sticking, excellent in feeling in use and giving an excellent body-care effect to the whole body. CONSTITUTION:An objective component containing (A) 0.01-10wt.% cationic surfactant (e.g. tetraalkylammonium salt or alkylpyridinium salt) and/or a cationic high polymer (e.g. cationized cellulose), (B) 1-30wt.% ester oil, e.g. isopropyl myristate or ethylene glycol monostearate and (C) 1-20wt.% polysiloxane, e.g. a linear methylpolysiloxane or a methylphenylpolysiloxane. The above-mentioned composition can prevent roughness of the skin and desquamation and keep the skin moist and a habitual use thereof for a long period can show an effect for improvement and prevention of the dry skin.
PURPOSE: To investigate peripapillary atrophy and macular chorioretinal scars in eyes affected by multifocal choroiditis and panuveitis.
METHODS: This retrospective cohort study reviewed the medical records, fundus photographs, and spectral-domain optical coherence tomographic scans of 31 eyes from 19 patients.
RESULTS: Patients had a mean age of 45 years (range 24-69 years). The average follow-up duration was 7 years (range, 2.5-14.5 years), with 14 patients undergoing immunosuppressive treatment. In the group of 31 eyes, 20 showed peripapillary plumes of ill-defined hyperreflectivity at the termination border of the retinal pigment epithelium. These plumes, extending from bare Bruch membrane to the outer nuclear layer, sometimes undermined the adjacent retinal pigment epithelium. They responded to corticosteroid treatment and resembled the material under the retinal pigment epithelium in acute lesions. Among 20 eyes with these peripapillary inflammatory lesions, 16 (80%) experienced increased atrophy, in contrast to none in the eyes without these lesions ( P < 0.001). Similar patterns were observed at the edges of macular chorioretinal atrophy. This observation occurred in patients using immunosuppressive medication who were otherwise thought to be under adequate control.
CONCLUSION: In patients with multifocal choroiditis and panuveitis, previously unrecognized plumes of smoldering inflammatory activity at the borders of chorioretinal atrophy appears to be linked to atrophy expansion. The recognition of this phenomenon may require a reappraisal of treatment of multifocal choroidopathies to help mitigate the expansion of atrophy in these eyes.
An apparatus can be used to generate acoustic imaging pulse sequences and receive corresponding echoes elicited by the acoustic imaging pulse sequences. An acoustic radiation force (ARF) pulse sequence can be generated to agitate a contrast medium in a tissue region between the acoustic imaging pulse sequences. A decorrelation between images corresponding to the received echoes can be determined. A weighting map can be applied to an image to weight a region of the image corresponding to a spatial location of the contrast medium using the determined decorrelation. In an example, the receiving of corresponding echoes elicited by the acoustic imaging pulse sequences can include receiving acoustic energy having a range of frequencies offset from a fundamental frequency associated with the acoustic imaging pulse sequences. An acoustic imaging pulse sequence can include a pulse having an inverted amplitude envelope with respect to another pulse included in the sequence.
In this phase 2, open-label randomized, placebo-controlled trial, investigators will test whether prophylactic high-dose IV Mg administration attenuates the risk of HIOC-associated AKI in patients with malignant mesothelioma undergoing surgery with HIOCC. Investigators will randomly assign 130 patients to receive IV Mg versus an equal volume of normal saline (0.9% NS) placebo, of whom it is anticipated 80 will complete the study. Investigators will also collect blood and urine pre- and postoperatively for exploration of secondary outcomes.

Investigators will screen for eligibility at participant's preoperative visit with their thoracic surgeon. Intravenous magnesium will be administered as a continuous infusion, soon after induction and stabilization by anesthesia in the operating room. The magnesium drip will start at 1 g/hour and will be titrated to achieve target levels of 3-5 mg/dl. The total duration of the infusion will be 24 hours.
AIM: The Kono-S anastomosis was introduced as a possible solution to the high surgical recurrence rates in Crohn's disease. However, this technique is known to be challenging, which is why it was originally performed in an extracorporeal setting. The aim of this case series was to assess safety, in terms of intra-/postoperative complications, and feasibility, in terms of successful performance of anastomosis, of a robot-assisted intracorporeal Kono-S anastomosis.
METHOD: This is a prospective single-centre consecutive case series. Patients were considered eligible if they were diagnosed with refractory Crohn's disease with significant bowel stenosis of the terminal ileum. All patients underwent robot-assisted intracorporeal Kono-S anastomosis. Perioperative care was provided according to the Enhanced Recovery After Surgery® protocol. Follow-up for postoperative complications was 30 days.
RESULTS: Twenty patients were included, of whom 11 (55%) were men. The median age was 30 years [interquartile range (IQR) 22-51 years] and the median BMI was 25 kg/m2 (IQR 19-28 kg/m2). Intracorporeal Kono-S anastomosis was successfully performed in all cases. The median operating time was 155 min (IQR 144-176 min) and the median length of stay was 3 days (IQR 1-5 days). No conversions or 30-day mortality were observed. One patient experienced anastomotic leakage, which was treated with radiologically guided drainage. A total of three patients experienced postoperative complications in the first 30 days.
CONCLUSION: Performance of intracorporeal robot-assisted Kono-S anastomosis seems safe and feasible in this case series for Crohn's disease. Since this is a first case series, further research is required to confirm results in a larger population-based cohort.
PURPOSE:To obtain an excellent hypotensive and vasodilating agent having high safety and free from side effect, by using hydrolyzed muscle of fishes and optionally egg yolk as active components. CONSTITUTION:Meat collected from fishes is crushed, water is added to the meat as necessary, and the product is subjected to hydrolysis by acid hydrolysis, alkali hydrolysis, enzymatic hydrolysis, etc. The hydrolyzed product is used as an active component of the objective hypotensive and vasodilating agent. For example, in the case of enzymatic hydrolysis, the crushed fish meat is warmed to the optimum temperature of the enzyme (20-60 deg.C), adjusted to pH3-9, added with a proteinase (e.g. pepsin or protease) and treated for 1-30hr. The treated product is neutralized and maintained at >=80 deg.C for 5-30min to deactivate the enzyme. The obtained decomposition liquid is used as it is, or as a peptide solution prepared by ultrafiltration or in the form of stock peptide solution or peptide as an active component of the objective agent. The agent may be used in combination with egg yolk to obtain a peroral drug.
BACKGROUND: The impact of sex on outcomes following surgical aortic valve replacement (SAVR) remains unclear. It has been proposed that females experience inferior outcomes, but this has yet to be conclusively established, particularly in the long term. The objective of this study is to identify discrepancies in postoperative outcomes between males and females following SAVR to better inform consideration for surgical intervention.
METHOD: We retrospectively reviewed the outcomes of 4,927 patients who underwent SAVR from 2004 to 2018 at our centre. In total, 531 propensity-matched males and females were included in the final analysis. The primary outcome was mortality at any point during the follow-up period. Secondary outcomes included various measures of postoperative morbidity. Follow-up duration was 15 years.
RESULTS: In SAVR all-comers, females experienced inferior short-term mortality, but equivalent mid-term and long-term mortality. Rates of mediastinal bleeding, sternal wound infections, sepsis, heart failure, and pacemaker insertion were all equivalent between the sexes; however, males experienced a higher rate of acute kidney injury and readmission for stroke at the longest follow-up while females experienced a longer intensive care unit and hospital length of stay. In a sub-analysis of isolated SAVR, males and females experienced equivalent early, mid, and late mortality. Of note, a trend towards increased aortic valve reoperation was noted in females at the longest follow-up.
CONCLUSIONS: Males and females experience equivalent long-term mortality following isolated SAVR. Sex is not an independent risk factor of poor outcomes post-SAVR; however, the increased preoperative risk profile of females requires diligent consideration.
Some studies have shown that simultaneous sucralfate administration in healthy volunteers reduced the extent of absorption (bioavailability) of single doses of the following: cimetidine, digoxin, fluoroquinolone antibiotics, ketoconazole, l-thyroxine, phenytoin, quinidine, ranitidine, tetracycline, and theophylline. Subtherapeutic prothrombin times with concomitant warfarin and sucralfate therapy have been reported in spontaneous and published case reports. However, two clinical studies have demonstrated no change in either serum warfarin concentration or prothrombin time with the addition of sucralfate to chronic warfarin therapy.

The mechanism of these interactions appears to be nonsystemic in nature, presumably resulting from sucralfate binding to the concomitant agent in the gastrointestinal tract. In all cases studied to date (cimetidine, ciprofloxacin, digoxin, norfloxacin, ofloxacin, and ranitidine), dosing the concomitant medication 2 hours before sucralfate eliminated the interaction. Because of the potential of sucralfate to alter the absorption of some drugs, sucralfate should be administered separately from other drugs when alterations in bioavailability are felt to be critical. In these cases, patients should be monitored appropriately.
Glucagon infusion in escalating manner at 12.5, 25, 37.5 and 50 ng/kg/min (each step for 60 min). At 30 and 60 mins of each infusion rate, we will administer a previously established questionnaire to assess overall nausea intensity.
The invention relates to methods and compositions for the inhibition of modulation of T cell costimulatory pathway by a pathogenic agent. More particularly, the invention relates to the inhibition of activation of a T cell costimulatory pathway, preferably, the CD28/B7 pathway, by a pyrogenic exotoxin. The method of the invention is based on the inhibition of the direct interaction of a superantigen with a specific site within the dimer interface of a CD28 family member, using immunomodulatory peptides. The invention further provides specific antagonist immunomodulatory peptides comprising an amino acid sequence derived from a dimer interface of a T cell costimulatory pathway member. Alternatively, said peptide comprises an amino acid sequence which specifically binds to an amino acid sequence within the dimer interface of a T cell costimulatory pathway member. Compositions comprising said peptides and methods for the treatment of immune-related disorders are also provided by the invention..
The invention discloses traditional Chinese medicine for treating yang qi exhaustion type somnolency disease. The traditional Chinese medicine is characterized by being prepared from the following raw materials in parts by weight: 15 parts of ginkgo root, 12 parts of angelica morri Hayata, 12 parts of moxibustion astragalus, 20 parts of Aleuritopteris hopeana (C. Chr.) Ching, 15 parts of oblongleaf betony herb or root, 15 parts of ligularia tsangchanensis, 20 parts of phytolacca flower, 20 parts of semen nigellae, 10 parts of calocybe gambosa, 15 parts of Taiwan begonia, 12 parts of acranthera, 12 parts of salvia scapiformis hance, 15 parts of satyrium ciliatum, 15 parts of Vaccinium laetum Diels,12 parts of piper cubeb, 10 parts of dyebark evodia fruit root leaf, 6 parts of Yunnan fructus galangae fruit, 12 parts of kali turgid, 15 parts of forestry greenstar root, 18 parts of dillseed, 15 parts of oxygraphis bunge, 20 parts of abdullah, 20 parts of stellaria yunnanensis and 5 parts of liquorice. The medicine disclosed by the invention can be used for effectively treating yang qi exhaustion type somnolency disease. Over the years, application of 100 patients proves that the effective rate reaches 100%, the curative effect is good and no recurrence is founded in follow-up visits after cure.
FIELD: medicine, pharmacy. SUBSTANCE: invention relates to medicinal preparations eliciting immunomodulating, anti-inflammatory, antitumor and antioxidant effects. Medicinal preparation (7 variants) comprises a mixture of two or three alkaline salts of 5-amino-2,3-dihydro-1,4-phthalazinedione. Method for production of medicinal preparation involves preparing indicated salts and their mixtures by carrying out cycles of processing the parent composites and treatment of intermediate composites up to preparing the end product with repeated using mother liquors in indicated process after isolation an intermediate composite from these solutions and the end product. The developed variants of medicinal preparation differ by duration and spectrum of effect and by pharmakokinetic parameters also and can be used by oral intake, intramuscular injection and for other medicinal procedures depending on purity of preparing alkaline salts. Proposed method for production of the preparation is highly technological process of small-waste pharmaceutical production. EFFECT: improved preparing method, valuable medicinal properties of preparation. 42 cl, 4 dwg, 3 tbl, 14 ex
Background: Western populations are losing the battle over healthy weight management, and excess body weight is a notable cancer risk factor at the population level. There is ongoing interest in pharmacological interventions aimed at promoting weight loss, including GLP-1 receptor agonists (GLP-1RA), which may be a useful tool to stem the rising tide of obesity-related cancers. Purpose: To investigate the potential of next generation weight loss drugs (NGWLD) like GLP-1RA in population-level chemoprevention.Research Design: We used the OncoSim microsimulation tool to estimate the population-level reductions in obesity and the potentially avoidable obesity-related cancers in Canada over the next 25 years.Results: We estimated a total of 71 281 preventable cancers by 2049, with 36 235 and 35 046 cancers prevented for females and males, respectively. Among the 327 254 total projected cancer cases in 2049, 1.3% are estimated to be preventable through intervention with NGWLD.Conclusions: Pharmacologic intervention is not the ideal solution for the obesity-related cancer crisis. However, these agents and subsequent generations provide an additional tool to rapidly reduce body weight and adiposity in populations that have been extremely challenging to reduce weight with standard diet and exercise approaches. Additional research is needed around approaches to prevent initial weight gain and maintain long-term weight loss.